ML21288A543: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot change)
(StriderTol Bot change)
Line 16: Line 16:


=Text=
=Text=
{{#Wiki_filter:October 15, 2021
{{#Wiki_filter:}}
 
U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555
 
==References:==
 
2021-SMT-0149 10 CFR 50.30
 
(1)  SHINE Medical Technologies, LLC letter to the NRC, âSHINE Medical
 
Technologies, LLC Application for an Operating License,â dated July 17, 2019 (ML19211C143)
 
(2)  NRC letter to SHINE Medical Technologies, LLC, âSHINE Medical
 
Technologies, LLC â Update to Operating License Application Technical Review Schedule (EPID No. L-2019-NEW-0004),â dated August 3, 2021 (ML21209A997)
 
(3)  SHINE Medical Technologies, LLC letter to the NRC, âSHINE Medical
 
Technologies, LLC Schedule Update,â dated September 2, 2021 (ML21245A055)
 
(4)  SHINE Medical Technologies, LLC letter to the NRC, âSHINE Medical
 
Technologies, LLC Overview of Phased Approach to Initial Facility Operations,â dated February 26, 2021 (ML21057A340)
 
SHINE Technologies, LLC Schedule Update â Expected Dates for Completion of Construction and Request for Receipt of Additional Radioactive Material Pursuant to 10 CFR Part 50.30, SHINE Technologies, LLC (SHINE) submitted an application for an operating license for a medical isotope production facility to be located in Janesville, WI (Reference 1). Via Reference 2, the NRC staff requested SHINE provide updated submission dates for the phased approach supplement and subsequent request to receive and possess radioactive material, as well as the current expected completion dates for each phase of construction, to enable the staff to establish a revised review schedule for the SHINE application. SHINE previously provided the estimated submission date for the application supplement for the phased approach to initial facility operations (Reference 3).
An overview of the phased approach to initial facility operations, including identification of the four phases of process equipment installation and operation, was provided via Reference 4.
SHINE estimates the following construction completion dates for each of the four phases:
 
⢠ Phase 1 construction substantially complete:  May 2023
⢠ Phase 2 construction substantially complete:  May 2023
⢠ Phase 3 construction substantially complete:  May 2024
⢠ Phase 4 construction substantially complete:  August 2025
 
SHINE estimates the submission date for the request to license certain byproduct, source, and special nuclear material to support initial facility operations to be April 2022.
 
3400 Innovation Ct. ⢠Janesville, WI 53546 ⢠877.512.6554 ⢠info@shinemed.com ⢠www.SHINEtechnologies.com
 
Document Control Desk Page 2 If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing, at 608/210-1735.
Very truly yours, James Costedio Vice President of Regulatory Affairs and Quality SHINE Technologies, LLC Docket No. 50-608 cc:
 
Project Manager, USNRC SHINE General Counsel Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health}}

Revision as of 18:45, 16 January 2022

Shine Technologies, LLC Schedule Update - Expected Dates for Completion of Construction and Request for Receipt of Additional Radioactive Material
ML21288A543
Person / Time
Site: SHINE Medical Technologies
Issue date: 10/15/2021
From: Jim Costedio
SHINE Health. Illuminated, SHINE Technologies
To:
Document Control Desk, Office of Nuclear Reactor Regulation
References
2021-SMT-0149
Download: ML21288A543 (2)
v • d • e


Text

Retrieved from "https://kanterella.com/w/index.php?title=ML21288A543&oldid=3390223"